[1]董高宏,丘福良,刘长安,等.DNMT3B通过Hippo信号通路促进肝癌细胞的增殖与侵袭[J].南方医科大学学报,2019,(12):1443-1452.[doi:10.12122/j.issn.1673-4254.2019.12.08]
 High expression of DNMT3B promotes proliferation and invasion of hepatocellular carcinoma cells via Hippo signaling pathway[J].Journal of Southern Medical University,2019,(12):1443-1452.[doi:10.12122/j.issn.1673-4254.2019.12.08]
点击复制

DNMT3B通过Hippo信号通路促进肝癌细胞的增殖与侵袭()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2019年12期
页码:
1443-1452
栏目:
出版日期:
2020-01-01

文章信息/Info

Title:
High expression of DNMT3B promotes proliferation and invasion of hepatocellular carcinoma cells via Hippo signaling pathway
作者:
董高宏丘福良刘长安邬 昊刘 彦
关键词:
肝癌DNMT3B预后意义恶性进展
Keywords:
hepatocellular carcinoma DNMT3B prognostic significance malignant progression
DOI:
10.12122/j.issn.1673-4254.2019.12.08
文献标志码:
A
摘要:
目的 探索DNMT3B 对肝癌细胞的增殖与侵袭的影响。方法 收集2008年5月~2013年5月在重庆医科大学附二院确诊的175例肝癌患者并制作成组织芯片,分析DNMT3B蛋白表达水平的差异与患者的预后情况及患者肿瘤无瘤生存率与肿瘤特异性生存率的关系。使用单因数与多因素Cox回归分析DNMT3B 的表达对肝癌患者预后的影响。使用小干扰RNA(siRNA) 与慢病毒过表达干扰DNMT3B 的表达,利用CCK-8及EDU染色检测肝癌细胞增殖情况,对细胞进行Transwell 实验检测细胞迁移侵袭能力分析。结果 免疫组化显示DNMT3B 蛋白在肝癌中的表达率(67.4%)高于配对癌旁组织的表达率(41.1%)。DNMT3B 的高表达与肿瘤大小(P=0.001)、血管侵犯(P=0.004)、肝内转移(P=0.018)密切相关。DNMT3B 高表达患者其肿瘤无瘤生存率与肿瘤特异性生存率低于DNMT3B 低表达患者(P<0.005)。沉默DNMT3B 显著抑制Huh-7 细胞增殖,Transwell 实验检测结果表明,与对照组相比沉默DNMT3B 抑制Huh-7 细胞的迁移与侵袭能力。Western blot 检测显示,沉默DNMT3B 的表达升高了LATS1 的表达水平,降低了YAP1 的表达,激活了Hippo 信号通路。同时,甲基化特异性PCR显示LATS1 的甲基化水平降低。结论 肝癌中DNMT3B的表达高于癌旁组织,并且DNMT3B 的高表达与患者的低生存率密切相关。沉默DNMT3B 抑制细胞增殖、迁移和侵袭能力。DNMT3B 主要通过甲基化LATS1 并抑制其表达,促进癌基因YAP1的表达进而抑制Hippo信号通路的抑癌作用,从而促进肝癌恶性发展。
Abstract:
Objective To explore the role of DNMT3B in regulating the proliferation and invasion of hepatocellular carcinoma (HCC) cells. Methods We collected the tumor tissues and adjacent tissues from a total of 175 patients with HCC diagnosed in the Second Affiliated Hospital of Chongqing Medical University between May, 2008 and May, 2013 to prepare the tissue microarrays. The association of the expression of DNMT3B with the prognosis and the tumor-free survival and tumor-specific survival rates of the patients was analyzed. Univariate and multivariate Cox regression analyses were used to analyze the effect of DNMT3B expression on the prognosis of HCC. We used RNA interference technique to knock down the expression of DNMT3B in Huh-7 hepatoma cells and observed the changes in cell proliferation using CCK-8 assay and EDU staining and in cell migration and invasion ability using Transwell assay. Results The positive rates of DNMT3B was significantly higher in HCC tissues than in paired adjacent tissues (67.4% vs 41.1%, P=0.015). A high DNMT3B expression in HCC was significantly associated with the tumor size (P=0.001), vascular invasion (P=0.004), and intrahepatic metastasis (P=0.018). The patients with high DNMT3B expressions had significantly lower tumor-free and tumor-specific survival rates than those with low DNMT3B expressions (P<0.005). In Huh-7 cells, silencing DNMT3B significantly inhibited the cell proliferation and inhibited cell migration and invasion. Western blotting showed that silencing DNMT3B obviously increased LATS1 expression, decreased the expression of YAP1, and activated Hippo signaling pathway. Methylation-specific PCR showed that the methylation level of LATS1 was decreased in the cells with DNMT3B silencing. Conclusion The expression level of DNMT3B is significantly higher HCC tissues than in the adjacent tissues, and the high expression of DNMT3B is closely related to the low survival rate of the patients. Silencing DNMT3B inhibits the proliferation, migration and invasion of HCC cells. DNMT3B promotes the progression of HCC primarily by enhancing the expression of YAP1 through methylation of LATS1 and inhibition of its expression, which inhibits the anti-cancer effect of Hippo signaling pathway.

相似文献/References:

[1]陈耿臻,韩慧,许铭炎,等. 重组腺病毒ADV-TK 基因的构建及其对肝癌细胞的杀伤作用[J].南方医科大学学报,2010,(08):1887.
 CHEN Geng-zhen,HU Hui,XU Ming-yan,et al. Construction of recombinant adenovirus containing TK gene and its effect against human liver cancer cells[J].Journal of Southern Medical University,2010,(12):1887.
[2]凌志海,孙权权,张耀伟,等.吉西他滨增强肝癌HepG2细胞体外辐射敏感性的机制研究[J].南方医科大学学报,2011,(12):1993.
[3]陈建发,李宇华,陈引香,等.Apollon siRNA提高肝癌细胞化疗敏感性的实验研究[J].南方医科大学学报,2011,(10):1701.
[4]杨义明,杜钢军,林海红.沙利度胺治疗肝癌的实验研究[J].南方医科大学学报,2005,(08):925.
 YANG Yi-ming,DU Gang-jun,LIN Hai-hong.Experimental study of thalidomide for treatment of murine hepatocellular carcinoma[J].Journal of Southern Medical University,2005,(12):925.
[5]季锡清,李朝龙,杨进城,等.血流阻断的缺血预处理技术在肝癌切除术中的应用[J].南方医科大学学报,2004,(01):66.
 JI Xi-qing,LI Chao-long,YANG Jin-cheng,et al.Application of ischemic preconditioning before hepatic vascular exclusion for resection of hepatocellular carcinoma[J].Journal of Southern Medical University,2004,(12):66.
[6]王素珍,孟维静,安洪庆,等.基于倾向指数匹配法的肝癌病人疗效评价[J].南方医科大学学报,2012,(09):1234.
[7]阳洁,覃贵慧,陈军泽.慢病毒介导shRNA靶向下调Cx26表达对人高侵袭性肝癌细胞上皮间质转化及侵袭的影响[J].南方医科大学学报,2014,(12):1743.
[8]肖芦山,邹雪晶,胡威,等.microRNA-107在肝癌中的表达及临床意义[J].南方医科大学学报,2016,(07):974.
[9]玉艳红,原彤彤,黄力毅,等.外周血单核细胞hFgl2蛋白表达与不同临床类型肝病的关系[J].南方医科大学学报,2013,(03):436.
[10]戴小珍,熊新,王兰,等.CXCR7-shRNA慢病毒载体对人肝癌细胞生长及侵袭能力的抑制作用[J].南方医科大学学报,2013,(07):994.

更新日期/Last Update: 2019-12-27